
Neuphoria Therapeutics Inc.
NEUPHealthcare|Biotechnology|US
$2.78
+0.01 (+0.36%)
DCF Value
$3103.96
Tangible Book / Share
$3.13
Cash / Share
$3.67
Ownership Breakdown
77.5%
Float
5.4M
Shares Outstanding
4.2M
Float Shares
Major Holders (17)
Combined: 105.4%
Holders of 5%+ from their latest Schedule 13D/13G filing in the last two years. Percentages are as of each filing date.
| Holder | Type | % of Class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Weston Nichols | Individual | 16.30% | 875,328 | Dec 29, 2025 | 13D/G |
| Lynx1 Capital Management LP | Partnership | 16.30% | 875,328 | Dec 29, 2025 | 13D/G |
| Shay Capital LLC | Other | 7.30% | 171,629 | Oct 31, 2025 | 13D/G |
| Shay Capital Holdings LLC | Holding company | 7.30% | 171,629 | Oct 31, 2025 | 13D/G |
| AdvisorShares Trust | Investment company | 5.78% | 312,895 | Oct 5, 2026 | 13D/G |
| Steven Boyd | HC, IN | 4.99% | 1,033,796 | Feb 14, 2025 | 13D/G |
| Armistice Capital, LLC | IA, OO | 4.99% | 1,033,796 | Feb 14, 2025 | 13D/G |
| Apeiron Investment Group Ltd. | Corporation | 4.50% | 72,618 | Jan 28, 2025 | 13D/G |
| Christian Angermayer | Individual | 4.50% | 72,618 | Jan 28, 2025 | 13D/G |
| Coastlands Capital Partners LP | Partnership | 4.23% | 228,594 | Jul 28, 2026 | 13D/G |
| Coastlands Capital LLC | HC, OO | 4.23% | 228,594 | Jul 28, 2026 | 13D/G |
| Coastlands Capital GP LLC | Other | 4.23% | 228,594 | Jul 28, 2026 | 13D/G |
| Coastlands Capital LP | IA, PN | 4.23% | 228,594 | Jul 28, 2026 | 13D/G |
| Matthew D. Perry | HC, IN | 4.23% | 228,594 | Jul 28, 2026 | 13D/G |
| Baselake Partners, LP | Partnership | 4.10% | 222,222 | Feb 6, 2026 | 13D/G |
| Baselake Management, LLC | IA, OO | 4.10% | 222,222 | Feb 6, 2026 | 13D/G |
| David Paolella | HC, IN | 4.10% | 222,222 | Feb 6, 2026 | 13D/G |
Insider Trades (13)
Last 4 quarters: 1,047,268 acquired · 0 disposed
| Insider | Position | Date | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Wilson David Ian | director | Jan 20, 2026 | AWARD | 8,537 | — | — | Form 4 |
| Davies Peter Miles Winston | director | Jan 20, 2026 | AWARD | 8,537 | — | — | Form 4 |
| Fisher Alan | director | Jan 20, 2026 | AWARD | 17,073 | — | — | Form 4 |
| Ryan Jane | director | Jan 20, 2026 | AWARD | 8,537 | — | — | Form 4 |
| Lynx1 Capital Management LP | 10 percent owner | Oct 21, 2025 | BUY | 639,110 | $5.14 | $3.3M | Form 4 |
| Lynx1 Capital Management LP | 10 percent owner | Oct 21, 2025 | OTHER | 0 | — | — | Form 4 |
| Papapetropoulos Spyros | director, officer: President and CEO | Aug 27, 2025 | AWARD | 34,559 | $8.27 | $285.8K | Form 4 |
| Papapetropoulos Spyros | director, officer: President and CEO | Apr 16, 2025 | AWARD | 27,000 | $5.16 | $139.3K | Form 4 |
| Papapetropoulos Spyros | director, officer: President and CEO | Apr 16, 2025 | AWARD | 270,000 | $5.16 | $1.4M | Form 4 |
| Davies Peter Miles Winston | director | Apr 16, 2025 | AWARD | 6,783 | — | — | Form 4 |
| Ryan Jane | director | Apr 16, 2025 | AWARD | 6,783 | — | — | Form 4 |
| Wilson David Ian | director | Apr 16, 2025 | AWARD | 6,783 | — | — | Form 4 |
| Fisher Alan | director | Apr 16, 2025 | AWARD | 13,566 | — | — | Form 4 |